FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA's Overreach on Compounded Peptides This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health